GLP-1 prescriptions are increasingly written in 10-minute appointments — sometimes through telehealth platforms that have no established relationship with the patient. The prescribing information for these drugs contains contraindications, monitoring recommendations, and dose adjustment guidance that most patients never hear. What follows is a stage-by-stage guide to the questions that matter, framed to help you make productive use of limited appointment time.
Before You Start
The questions at initiation set the trajectory for everything that follows.
Am I an appropriate candidate?
Absolute contraindications to GLP-1 therapy include personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and prior serious hypersensitivity reactions to these agents. Active or recent pancreatitis is also a contraindication in most cases. These should be explicitly screened before any prescription is written.
Beyond contraindications, ask about interactions with your current medication list. GLP-1s slow gastric emptying, which can alter the absorption profile of drugs that depend on predictable GI transit. Oral contraceptives are a notable example — some providers recommend a non-oral backup method or timing OCP doses relative to GLP-1 injection. Blood pressure and diabetes medications may need dose adjustment as the drug takes effect.
What labs should we baseline?
Standard pre-initiation labs:
- Comprehensive metabolic panel — liver function, kidney function, electrolytes
- HbA1c — critical for establishing diabetes status and tracking response
- Fasting lipid panel — GLP-1s tend to improve lipids; useful to document baseline
- TSH (thyroid) — thyroid disease is common, affects metabolism and weight, and needs to be tracked independently
- CBC — rule out anemia and other baseline abnormalities
- Ferritin — iron stores; GLP-1-mediated appetite suppression makes dietary iron intake less reliable, and ferritin often drops during weight loss
- 25-OH Vitamin D — deficiency is extremely common and affects muscle preservation, immune function, and mood
Many telehealth GLP-1 platforms skip labs entirely or offer only minimal panels. If your provider does not order baseline labs, request them. If you encounter resistance, ask specifically: "What lab changes should I watch for on this medication, and how will we catch them if we don't have a baseline?"
What's the titration schedule, and what are the decision points?
Standard titration schedules exist for each drug — semaglutide starts at 0.25 mg weekly for 4 weeks, tirzepatide at 2.5 mg weekly for 4 weeks — but these are minimum floors, not mandatory escalation timelines. Many providers move patients up on fixed 4-week calendars regardless of side effect burden, rate of weight loss, or patient-reported experience. This is a clinical shortcut that benefits the provider's schedule, not necessarily the patient.
Ask: "What would make you hold a dose rather than escalating?" and "If I'm losing weight faster than expected, does that change the escalation plan?"
What side effects should I call about versus what should I wait out?
The GI side effects of GLP-1s — nausea, delayed gastric emptying, constipation, occasional vomiting — are expected and typically self-limiting within weeks of a dose change. The symptoms that require contact:
- Persistent severe nausea or vomiting that makes it impossible to keep down liquids
- Right upper quadrant abdominal pain (gallbladder)
- Any fever with abdominal pain
- New or worsening depression or mood changes
- Vision changes (particularly in patients with diabetes — glycemic improvement can temporarily worsen diabetic retinopathy)
Get explicit guidance on this before you leave the first appointment. "Expected" and "concerning" are not obvious to a patient experiencing their first dose.
At Each Dose Escalation
Dose escalation appointments — or, for telehealth patients, the message exchange that triggers a new prescription — are where most complications originate from failure to individualize.
Is my current side effect burden acceptable before escalating? The purpose of the starting dose is tolerability establishment, not therapeutic weight loss. If significant nausea, fatigue, or GI symptoms persist at the current dose, escalating before they resolve stacks new drug effects on top of ongoing ones. Ask your provider explicitly whether your current tolerability profile warrants moving up.
Am I losing weight at an appropriate rate? Both extremes are clinically meaningful. Losing more than 1–1.5% of body weight per week dramatically increases gallstone risk and lean muscle loss. Losing less than 0.5% over several weeks at a dose where side effects are resolved may indicate that escalation is appropriate, or it may indicate non-adherence to behavioral components. Ask what rate your provider is targeting, and make sure you have a shared reference point.
Do any of my other medications need adjustment? As blood sugar improves in diabetic patients, diabetes medications — particularly sulfonylureas and insulin — may need downward adjustment to avoid hypoglycemia. Blood pressure medications may need adjustment as weight loss improves vascular function. This review should happen at every escalation visit.
Note(The dose escalation trap)
Many GLP-1 prescribers follow pharmaceutical company titration schedules as written — escalating every 4 weeks regardless of patient experience. The rationale in clinical trials was to move patients to the dose that demonstrated efficacy in trial populations. In practice, many patients achieve meaningful appetite suppression and weight loss at lower doses. The minimum effective dose is the goal, not the maximum approved dose. A provider who escalates without asking how you're doing at the current dose is running a protocol, not practicing individualized medicine.
At a Plateau
Weight loss plateaus are physiologically expected. Metabolic rate adapts downward as body weight decreases, and the body becomes more efficient. This is not failure. But it can also indicate addressable problems.
Is this a true metabolic plateau or an optimization opportunity? Before changing the drug, review the behavioral components: protein intake, resistance training, sleep, alcohol. The most common cause of stalled GLP-1 weight loss is caloric drift — the appetite suppression that was dramatic at initiation has become familiar, and food intake has crept back up. A food log review is appropriate before any pharmacological change.
Should we escalate dose, change the drug, or add something? Each option has different tradeoffs. Dose escalation at plateau has diminishing returns if the current dose already provides good appetite suppression. Switching from semaglutide to tirzepatide (which adds GIP receptor agonism) has shown meaningful additional weight loss in patients who plateau on semaglutide. Adding weight loss adjuvants (bupropion/naltrexone, phentermine/topiramate) is another option, though medication interactions require careful review.
Have we ruled out secondary causes? Ask specifically: "Should we check thyroid function, cortisol, and fasting insulin?" Secondary hypothyroidism and elevated cortisol (from chronic stress or subclinical Cushing's) both resist weight loss pharmacologically. If these haven't been checked since baseline, a plateau is the right moment.
At Maintenance
Reaching goal weight is not the end of the clinical conversation — it's where a new set of decisions begins.
Can we try a lower maintenance dose? Most patients required for weight loss were established in trials using maximal doses. Many patients maintain weight effectively at doses lower than the loss-phase dose. A trial of dose reduction — with agreed monitoring criteria for what constitutes weight regain requiring return to a higher dose — is worth requesting.
Should I get a DEXA scan? DEXA (dual-energy X-ray absorptiometry) measures body fat percentage, lean mass, and bone density separately. After losing significant weight, the composition of what you lost matters. Patients who lost substantial lean mass alongside fat have a higher risk of metabolic slowdown and regain. Knowing your lean mass trajectory informs decisions about protein, resistance training, and maintenance dose. It also establishes a bone density baseline — weight loss is associated with reduced bone density, particularly in older patients.
What does long-term therapy look like? Obesity is a chronic condition with a strong genetic and neurobiological component. For most patients, stopping GLP-1 therapy leads to weight regain over 12–18 months as appetite returns to pre-treatment levels. This is not a personal failure — it reflects the underlying biology. Have the explicit conversation about what long-term or indefinite therapy looks like, what that implies for your health monitoring, and what a realistic maintenance plan is.
Considering Stopping
The stopping conversation requires the same clinical rigor as the starting conversation.
What is my realistic regain risk? Published data from semaglutide withdrawal studies show approximately two-thirds of lost weight returning within one year of stopping. Tirzepatide withdrawal data show similar patterns. Individual risk depends on how much weight was lost, how long the medication was used, and whether behavioral modifications have been consolidated. Ask your provider to give you a realistic number, not a reassurance.
What do I need to have in place before stopping? The behavioral infrastructure that should have been built during weight loss — protein targets, resistance training habits, sleep hygiene, reduction in processed food intake — should be well established before discontinuation. If these habits are not consolidated, the likelihood of significant regain is very high. A provider who is willing to help you stop without assessing these fundamentals is not doing right by you.
Is a taper appropriate? Cold cessation versus gradual tapering has not been definitively studied. Clinical experience suggests tapering may reduce the abruptness of appetite return, giving patients more time to adjust. Discuss whether your specific drug and dose make tapering a viable option.
Labs That Matter, by Stage
| Stage | Key Labs |
|---|---|
| Before starting | CMP, HbA1c, lipids, TSH, CBC, ferritin, vitamin D |
| Every 3–6 months | CMP, HbA1c (if diabetic), lipids |
| If muscle concerns arise | Ferritin, vitamin D, albumin |
| At plateau | TSH, cortisol (AM), fasting insulin |
| After significant loss | DEXA scan, bone density if over 50 |
| Before stopping | HbA1c, lipids (to document improvement) |
Note(Telehealth GLP-1 providers and lab monitoring)
Many telehealth platforms that prescribe GLP-1s do so with minimal or no required lab monitoring. This is not consistent with standard of care for these medications. If your telehealth provider does not discuss baseline labs or follow-up monitoring, consider whether this is the right provider for a medication that will meaningfully alter your metabolic parameters. Requesting labs and having them dismissed is a signal worth taking seriously.
User Sentiment
Example(What the community says)
The most consistent complaint in GLP-1 communities is the sense of being managed on a protocol rather than treated as an individual. "My provider just escalates me every 4 weeks whether I need it or not" is one of the most common refrains. Patients who report good outcomes consistently describe providers who asked questions at each visit — about side effects, rate of loss, and how they were actually feeling — rather than providers who simply renewed prescriptions. Lab monitoring is another frequent gap: many patients report that nobody ordered labs before starting, and nobody has ordered them since. The patients who pushed for labs and got them report feeling significantly more informed about what the medication was doing to their body.
Who It's For
Anyone currently on or considering GLP-1 therapy, particularly patients using telehealth platforms where appointment time is extremely limited. Also relevant for patients who have been on these medications for months without a structured monitoring conversation with their provider, or anyone who has hit a plateau and doesn't know what to do next.
Summary(The short version)
GLP-1 therapy unfolds across distinct stages, and each stage has specific clinical questions that matter. Before starting: establish contraindications, baseline labs, and what counts as a concerning side effect. At escalation: confirm your current tolerability and loss rate before moving up. At plateau: review behavioral components and consider thyroid/cortisol workup before changing drugs. At maintenance: discuss dose reduction, DEXA, and long-term plan. Before stopping: understand regain risk and confirm behavioral habits are consolidated. The minimum standard of care includes baseline labs and follow-up monitoring — if your provider isn't offering this, ask for it directly.